59831 Convection-Enhanced Delivery of Topotecan Induces IL-1β-Associated Inflammation in Glioblastoma

View at publisher Summarise with VIRAT
Authors: Anthony J. Tang, Damian E Teasley, Nicholas B. Dadario, Alan Chen, Nathaniel W. Rolfe, Misha Amini, Nkechime Ifediora, Mitchell Dees, Angeliki Mela, Athanassios Dovas, Brianna Pereira, Ashwin Viswanathan
+17 more Aayushi Mahajan, Nelson Humala, Julia Lynn Furnari, Corina P. Kotidis, Hannah Haile, Nadine Khoury, Arjun Rohit Adapa, Nathan J. Winans, Michael Argenziano, Colin P. Sperring, Nina T. Yoh, Liang Lei, Brian J. A. Gill, Peter A. Sims, Jack Grinband, Peter Canoll, Jeffrey N. Bruce
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: In our clinical trial using convection-enhanced delivery (CED) of topotecan (TPT) in patients with glioblastoma, CED TPT effectively reduced proliferating tumor cells. However, all patients ultimately experienced recurrence, and post-treatment tissue exhibited increased inflammatory cytokines and mesenchymal signatures. One of the most upregulated inflammatory cytokines, IL-1β, is associated with poor survival in glioblastoma. Further, local antagonism of IL-1β has been shown to prolong survival in tumor-bearing mice. METHODS: We conducted in vitro studies using human glioma and microglia cell lines, in monoculture and coculture, and measured IL-1β expression using qPCR and ELISA. We also performed single-cell RNA sequencing (scRNA-seq) on acute human glioblastoma slices treated with TPT ex vivo. Finally, we analyzed IL-1β expression following CED TPT treatment using scRNA-seq in a syngeneic mouse glioma model. RESULTS: GSEA using bulk RNA sequencing data from the CED TPT clinical trial demonstrated a trend toward upregulation of the IL-1 family signaling reactome (NES = 1.57, p = 0.06). In vitro, TPT treatment of glioma-microglia cocultures resulted in significant IL-1β upregulation at both mRNA and protein levels. Acute human glioblastoma slices treated with TPT ex vivo demonstrated increased IL-1β expression in a subpopulation of myeloid cells. Seven-day CED TPT treatment led to significant upregulation of IL-1β, predominantly in myeloid cells. CONCLUSIONS: TPT treatment induces IL-1β expression across in vitro and ex vivo glioblastoma models, as well as in vivo CED-treated tumors, with myeloid cells as a primary source. These findings support further investigation into the role of IL-1β in mediating TPT-induced inflammation in glioma. We are currently planning experiments to test the therapeutic potential of IL-1β blockade, such as with anakinra, as an adjunct to TPT treatment to reduce pro-tumor inflammation and improve outcomes in glioblastoma.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Neuroinflammation and Neurodegeneration Mechanisms Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
312–313
Publication date
26 March 2026
Language
EN